bjective: To investigate prognostic significance of HER2/neu expression and different clinicopathological parameters in patients with early gastric cancer (EGC) without lymph node metastasis (pN0). Methods: Data of 70 patients with N0 EGC undergoing radical gastrectomy and complete follow-up, and whose histopathological paraffin blocks were available were collected. The histopathological sections were examined for Her-2/neu expression by immunohistochemical sataining, and the relations of Her-2/neu status and other clinicopathological factors with the outcomes of the patients were analyzed. Results: Her-2/neu positive expression rate was 25.0% of all tissue sections. There was no significant association between Her-2/neu expression and age, gender, or tumor size, differentiation and depth of invasion (all P>0.05). The overall 5-year survival rate was 87.8% for the entire group of patients. Univariate analysis showed that gender, age, tumor size, depth of invasion, and degree of differentiation had no significant influence on survival of the patients (all P>0.05). The 5-year survival rate in patients with Her-2/neu positive expression was 72%, while in those with negative expression was 93%, and the difference was statistically significant (P<0.05). Multivariate regression analysis showed that Her-2/neu expression was a risk factor for prognosis (OR=5.036, P=0.035). Conclusion: Her-2/neu expression is a risk factor for prognosis of pN0 EGC patients, and has potential value for guiding clinical treatment of EGC.